Generic Prescribing Incentives: How States Are Cutting Drug Costs by Rewarding Generic Use

When you pick up a prescription, you might not realize that the decision between a brand-name drug and its generic version isn’t just about your doctor’s preference-it’s often shaped by rules written in state capitals. Across the U.S., states have been quietly building systems to nudge doctors, pharmacists, and patients toward cheaper generic medications. These aren’t bans. They’re incentives. And they’re working-sometimes better than anyone expected.

Why States Care About Generic Drugs

Generic drugs are chemically identical to their brand-name counterparts but cost 80% to 85% less. That’s not marketing. That’s fact. In 2023, generics made up nearly 90% of all prescriptions filled in the U.S., but they accounted for just 20% of total drug spending. That gap is why states are investing so much effort into encouraging their use.

Medicaid, the government health program for low-income people, spends billions each year on prescriptions. In 2019, 46 out of 50 states had Preferred Drug Lists (PDLs) to control costs. These lists identify which drugs-mostly generics-are the most cost-effective. If a doctor prescribes a drug not on the list, the patient pays more, or the pharmacy must get special approval. It’s not about restricting care. It’s about making sure the money spent on drugs actually delivers value.

How States Push for Generics

States use three main tools to encourage generic use: copay differentials, pharmacist substitution rules, and preferred drug lists.

Copay differentials are the most direct. If your brand-name drug costs $50, but the generic is $10, your copay might be $15 for the brand and $5 for the generic. You’re not forced to choose the cheaper option, but the math makes it obvious. A 2000 Kaiser Family Foundation study showed that while pharmacy profits from dispensing generics dropped to just 8 cents more than brand-name drugs, patient copays widened dramatically-making the choice easier for people.

Pharmacist substitution is where things get interesting. In some states, pharmacists can swap a brand-name drug for a generic without asking you. That’s called presumed consent. In others, they have to get your permission first-explicit consent. A 2018 NIH study found that states with presumed consent saw a 3.2 percentage point increase in generic dispensing. That’s not a small bump. If all 39 explicit consent states switched, they could save $51 billion a year.

Preferred Drug Lists are the most common tool. Forty-six states used them in 2019. But here’s the catch: they’re only as good as the data behind them. If a brand-name drug offers a big rebate to Medicaid, it might still end up on the list-even if a cheaper generic exists. That’s why some states review their lists quarterly. Others do it once a year. The more frequent the review, the more responsive the system.

What Doesn’t Work

You’d think mandatory substitution-forcing pharmacists to swap generics-would work best. But research shows it doesn’t. Why? Because pharmacists already have a financial reason to dispense generics. They make more profit on them. So adding a law doesn’t change behavior much.

Same goes for paying pharmacists extra to hand out generics. The Department of Health and Human Services found these incentives rarely move the needle. The real leverage is with the patient. When people feel the cost difference at the counter, they change their behavior.

The Hidden Problem: When Generics Disappear

Here’s the twist: the very system meant to save money can sometimes make generics harder to find.

The Medicaid Drug Rebate Program requires drug makers to pay rebates to states based on the drug’s price. But in five specific situations-like when input costs rise, or a drug faces a shortage-the rebate can become so high that the manufacturer loses money, even if they don’t raise the price. That’s not a glitch. It’s how the math works.

Avalere Health found this leads to drug withdrawals. If a generic becomes unprofitable under Medicaid rules, the maker may stop producing it. That means fewer options. More shortages. And sometimes, patients end up back on expensive brand-name drugs.

This isn’t theoretical. It’s happened in multiple states. The system rewards low prices, but doesn’t account for the volatility of generic markets. States are starting to notice.

The 340B Program and Its Complications

Another layer comes from the 340B Drug Pricing Program. Created in 1992, it lets safety-net hospitals and clinics buy drugs at steep discounts-often 20% to 50% off. But here’s the problem: when those same clinics serve Medicaid patients, states have to reimburse them based on what they actually paid, not what the drug list says.

In 2016, CMS made it clear: states can’t pay more than the 340B ceiling price. That means if a clinic buys a generic for $2, the state can’t reimburse $5 just because that’s what’s on the list. This forces states to track actual acquisition costs, not just wholesale prices. It’s complicated. It’s administrative. But it’s necessary to prevent overpayment.

What’s Next? The $2 Drug List

At the federal level, CMS is testing a new idea: the Medicare $2 Drug List. It’s simple. For a handful of low-cost generics, patients pay just $2-no matter what their plan says. No prior authorization. No copay tiers. Just $2.

It’s still voluntary and only for Medicare Part D right now. But states are watching closely. If it cuts costs and increases adherence, it could become a model for Medicaid programs. Imagine if every state adopted a similar approach. For drugs like metformin, lisinopril, or levothyroxine, $2 copays could make adherence skyrocket.

Why This Matters to You

Whether you’re on Medicaid, private insurance, or paying out of pocket, these state policies affect your access and your wallet. If your state uses presumed consent, you might get a generic without even asking. If your copay is lower for generics, you’re being financially rewarded for choosing wisely.

But it’s not perfect. Some generics vanish because the rebate system breaks. Some patients still pay too much because the system isn’t updated fast enough. And not every state has the same rules.

The goal isn’t to eliminate brand-name drugs. It’s to make sure generics-the safe, effective, cheaper alternatives-are the default choice. Because when they are, everyone wins: patients pay less, insurers spend less, and the system becomes more sustainable.

What You Can Do

Ask your pharmacist: “Is there a generic version of this?” If there is, and you’re paying more than $10 for it, ask why. Check your plan’s formulary. See if your state has a Preferred Drug List. You might be surprised how much you can save.

Don’t assume your doctor knows the cost differences. Many don’t. But you do. And that gives you power.

Frequently Asked Questions